Status:
COMPLETED
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)
Lead Sponsor:
Procter and Gamble
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmfu...
Eligibility Criteria
Inclusion
- Cardiac symptoms for at least 20 minutes within past 6 hours;
- Will undergo primary PCI;
- Has ECG evidence of acute high risk ST elevation myocardial infarction;
- Willing and able to be followed for at least 12 months.
Exclusion
- Isolated low risk inferior wall myocardial infarction;
- Received fibrinolytic therapy;
- History of complement deficiency;
- Suspected neisserial infection;
- Participating in other investigational study;
- Pregnancy;
- Previous enrollment.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
5745 Patients enrolled
Trial Details
Trial ID
NCT00091637
Start Date
April 1 2004
End Date
May 1 2007
Last Update
November 18 2023
Active Locations (349)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntsville Hospital
Huntsville, Alabama, United States, 35801
2
Mayo Clinic Hospital
Phoenix, Arizona, United States, 85054
3
North Phoenix Heart Center
Phoenix, Arizona, United States
4
Northwest Medical Center
Tucson, Arizona, United States, 85741